Dr. Reddy’s Pays $5M For Child Packaging Violation

The Indian pharmaceutical company sold drugs in the United States in packaging that hadn’t been tested for child safety.

Dr. Reddy's / Image: Business Line
Dr. Reddy's / Image: Business Line

A December 18th Reuters article noted the resolution of a U.S. probe regarding the child safety aspect of Dr. Reddy’s packaging. According to the court papers, Dr. Reddy’s sold prescription drugs in the United States without testing the packaging for child safety. The company disagreed with the allegations, but has agreed to pay the settlement to put the issue to rest.

The violation dates back to 2011 when The Justice Department alleged that five types of drugs manufactured by Dr. Reddy’s wouldn’t pass the United States’ tests to determine child resistance. The negligence was a violation of the Consumer Product Safety Act as the drugs were not sold in packaging designed to prevent accidental ingestion by children. In addition to the financial penalty, Dr. Reddy’s is required to maintain a program to ensure compliance with consumer protection laws and report to the Consumer Product Safety Commission.

Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?